Optimised Post-discharge Care in Older Patients After Surgery for Colon Cancer (ERAS 3.0)
Launched by COPENHAGEN UNIVERSITY HOSPITAL AT HERLEV · Jan 26, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The clinical trial titled "Optimised Post-discharge Care in Older Patients After Surgery for Colon Cancer (ERAS 3.0)" aims to explore whether a special program can help older, frail patients recover better after surgery for colon cancer. This program, known as ERAS 3.0, starts once patients leave the hospital and includes a thorough health check, advice on nutrition from a dietitian, and guidance on physical activities they can do at home. Participants will be randomly assigned to either receive this enhanced care or standard post-surgery care, and their progress will be monitored at various times after discharge.
To be eligible for this study, participants must be at least 65 years old, have a specific level of frailty, and need to have undergone a certain type of colon surgery without complications or the creation of a stoma (an opening in the abdomen). The trial is not yet recruiting, but interested individuals should be aware that they need to provide informed consent to join and will be expected to follow the program and attend follow-up appointments at home and at the clinic. Overall, this trial hopes to find ways to improve recovery experiences for older patients after surgery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 65+
- • Clinical Frailty Scale preoperative score 4-7
- • Nutritional Risk Screening tool (NRS 2002) \> 3
- • Elective colonic resection
- • No stoma planned
- • Minimally invasive surgical approach (laparoscopic or robotic)
- • Patients discharged to own home
- • Informed consent to participate
- Exclusion Criteria:
- • Stoma creation during index surgery
- • Conversion to laparotomy
- • Major complications following surgery (Clavien-Dindo \>3a)
- • Participation in other randomised trials in conflict with the protocol and end- points of the ERAS 3.0 project
- • Discharged with tube feeding and parenteral nutrition (partially or completely)
- • Known food allergies to dairy or any other ingredient contained in the nutrition package
- • Incapable of providing informed consent
- • Discharge to 24-hour municipal rehabilitation facility
- • All conditions including psychological, geographical, and social factors that could hinder adherence to the trial protocol
- • Neoadjuvant radio- or chemotherapy
About Copenhagen University Hospital At Herlev
Copenhagen University Hospital at Herlev is a leading academic medical center in Denmark, dedicated to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the hospital leverages its multidisciplinary expertise and state-of-the-art facilities to conduct rigorous studies aimed at improving patient outcomes and advancing medical knowledge. With a strong commitment to ethical standards and patient safety, Copenhagen University Hospital at Herlev collaborates with researchers, healthcare professionals, and industry partners to explore new treatment modalities and enhance the standard of care across various medical fields.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Herlev, , Denmark
Patients applied
Trial Officials
Jacob Rosenberg, Professor, dr. med.
Study Director
Center of Perioperative Optimisation, Copenhagen University Hospital at Herlev
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported